Sr. Director, Scientific Communications & Publications

About Eidos Therapeutics & BridgeBio Pharma

Eidos Therapeutics, an affiliate of BridgeBio Pharma, is a commercial stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Attruby (acoramdis) is an orally administered small molecule designed to stabilize TTR, a best-in-class treatment aiming to halt the progression of ATTR diseases.

BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs. 

Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe. 

To learn more about our story and company culture, visit us at eidostx.com/ | https://bridgebio.com

Who You Are

The Senior Director, Publications and Scientific Communications will be responsible for the development and tactical execution of acoramidis publications, scientific communication, and scientific training materials. This role ensures the quality and compliance of scientific and medical documents, aligning publication initiatives with organizational goals and medical strategic imperatives. The ideal candidate will bring expertise in scientific communications, publications planning, and medical affairs, with a strong background in real-world evidence (RWE) publications. 

Responsibilities

• Develop and execute the publication strategy for real-world evidence (RWE) studies, ensuring alignment with medical strategic objectives and compliance with industry best practices (e.g., GPP, ICMJE, PRISMA, CONSORT, etc)
• Lead the development, review, and submission of manuscripts, abstracts, posters, and presentations across clinical trials, real-world evidence studies, and health economics outcomes research (HEOR)
• Collaborate with internal and external authors, key opinion leaders (KOLs), and research partners to develop high-impact scientific publications
• Ensure timely and high-quality execution of publication plans, partnering with cross-functional stakeholders and external agencies
• Drive the development of medical communication strategies and materials to support medical affairs team and cross-functional partners, including for internal training
• Identify opportunities for integrating RWE into the broader scientific communication strategy. 

No matter your role at BridgeBio, successful team members are:

• Patient Champions, who put patients first and uphold strict ethical standards
• Entrepreneurial Operators, who drive toward practical solutions and have an ownership mindset
• Truth Seekers, who are detailed, rational, and humble problem solvers
• Individuals Who Inspire Excellence in themselves and those around them
• High-quality executors, who execute against goals and milestones with quality, precision, and speed

Education, Experience & Skills Requirements

• Advanced degree (PhD, PharmD, MD, or equivalent) in life sciences, medicine, or related field 
• 7+ years of experience in scientific publications, medical communications, or medical affairs within the pharmaceutical/biotech industry 
• Strong expertise in real-world evidence publications, including experience publishing observational studies, registry data, and HEOR findings 
• Proven track record of leading publication strategies and delivering high-impact peer-reviewed publications and congress materials 
• Deep understanding of scientific writing, data interpretation, and statistical concepts related to clinical and real-world research 
• Familiarity with publication management systems (eg: iEnvision) and strong knowledge of industry guidelines and best practices (GPP, ICMJE, etc) 
• Strong project management skills, with the ability to manage multiple priorities in a fast-paced environment 
• Preferred:  
  • CMPP certification 
  • Experience in cardiology and/or rare diseases 
  • Prior medical writing experience 

What We Offer

• Patient Days, where we are fortunate to hear directly from individuals living with the conditions we are seeking to impact throughout the year and learn how we can improve our efforts
• A culture inspired by our values: put patients first, think independently, be radically transparent, every minute counts, and let the science speak
• An unyielding commitment to always putting patients first. Learn more about how we do this here
• A de-centralized model that enables our program teams to focus on advancing science and helping patients. Our affiliate structure is designed to eliminate bureaucracy and put decision-making power in the hands of those closest to the science
• A place where you own the vision – both for your program and your own career path
• A collaborative, fast-paced, data-driven environment where we inspire ourselves and each other to always perform at the top of our game
• Access to learning and development resources to help you get in the best professional shape of your life
• Robust and market-competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs)
• Flexible PTO
• Rapid career advancement for strong performers
• Potential ability to work on multiple BridgeBio Pharma programs across multiple therapeutic areas over time 
• Partnerships with leading institutions
• Commitment to Diversity, Equity & Inclusion